[go: up one dir, main page]

WO2016011201A3 - Epha4 cyclic peptide antagonists for neuroprotection and neural repair - Google Patents

Epha4 cyclic peptide antagonists for neuroprotection and neural repair Download PDF

Info

Publication number
WO2016011201A3
WO2016011201A3 PCT/US2015/040649 US2015040649W WO2016011201A3 WO 2016011201 A3 WO2016011201 A3 WO 2016011201A3 US 2015040649 W US2015040649 W US 2015040649W WO 2016011201 A3 WO2016011201 A3 WO 2016011201A3
Authority
WO
WIPO (PCT)
Prior art keywords
epha4
neuroprotection
cyclic peptide
peptide antagonists
neural repair
Prior art date
Application number
PCT/US2015/040649
Other languages
French (fr)
Other versions
WO2016011201A2 (en
Inventor
Elena B. Pasquale
Philip Dawson
Stefan J. RIEDL
Erika OLSON
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
The Scripps Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute, The Scripps Research Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Priority to EP15821503.8A priority Critical patent/EP3169344B1/en
Priority to JP2017501706A priority patent/JP6847824B2/en
Priority to US15/326,442 priority patent/US10322161B2/en
Publication of WO2016011201A2 publication Critical patent/WO2016011201A2/en
Publication of WO2016011201A3 publication Critical patent/WO2016011201A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present specification discloses APY cyclic peptides having EphA4 antagonistic activity, pharmaceutical compositions containing such EphA4 antagonists, and methods and uses of treating an EphA4-based disease, disorder or pathology in an individual using such APY cyclic peptides or pharmaceutical compositions.
PCT/US2015/040649 2014-07-15 2015-07-15 Epha4 cyclic peptide antagonists for neuroprotection and neural repair WO2016011201A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP15821503.8A EP3169344B1 (en) 2014-07-15 2015-07-15 Epha4 cyclic peptide antagonists for neuroprotection and neural repair
JP2017501706A JP6847824B2 (en) 2014-07-15 2015-07-15 EPHA4 Cyclic Peptide Antagonist for Neuroprotection and Nerve Repair
US15/326,442 US10322161B2 (en) 2014-07-15 2015-07-15 EPHA4 cyclic peptide antagonists for neuroprotection and neural repair

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462025002P 2014-07-15 2014-07-15
US62/025,002 2014-07-15

Publications (2)

Publication Number Publication Date
WO2016011201A2 WO2016011201A2 (en) 2016-01-21
WO2016011201A3 true WO2016011201A3 (en) 2016-03-10

Family

ID=55079168

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/040649 WO2016011201A2 (en) 2014-07-15 2015-07-15 Epha4 cyclic peptide antagonists for neuroprotection and neural repair

Country Status (4)

Country Link
US (1) US10322161B2 (en)
EP (1) EP3169344B1 (en)
JP (1) JP6847824B2 (en)
WO (1) WO2016011201A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011812A1 (en) * 2015-07-15 2017-01-19 Sanford Burnham Prebys Medical Discovery Institute Modified epha4 cyclic peptide antagonists for neuroprotection and neural repair
WO2019213620A1 (en) * 2018-05-04 2019-11-07 Iron Horse Therapeutics, Inc. Epha4 cyclic peptide antagonists and methods of use thereof
US20220306690A1 (en) * 2019-06-07 2022-09-29 The Curators Of The University Of Missouri Peptide inhibitors for the inhibition of hiv capsid
WO2024233346A1 (en) * 2023-05-05 2024-11-14 Sanford Burnham Prebys Medical Discovery Institute Epha4 antagonists and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180823A1 (en) * 2002-09-24 2004-09-16 Pasquale Elena B. Novel agents that modulate Eph receptor activity
US20080254023A1 (en) * 2004-09-08 2008-10-16 The University Of Queensland Treating Gliosis, Glial Scarring, Inflammation or Inhibition of Axonal Growth in the Nervous System by Modulating Eph Receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040180823A1 (en) * 2002-09-24 2004-09-16 Pasquale Elena B. Novel agents that modulate Eph receptor activity
US20080254023A1 (en) * 2004-09-08 2008-10-16 The University Of Queensland Treating Gliosis, Glial Scarring, Inflammation or Inhibition of Axonal Growth in the Nervous System by Modulating Eph Receptor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CARNEGIE: "Structure And Properties Of A Homologue Of Glutathione.", BIOCHEM. J., vol. 89, 1963, pages 471 - 478, XP055385037 *

Also Published As

Publication number Publication date
WO2016011201A2 (en) 2016-01-21
EP3169344A4 (en) 2018-04-04
JP6847824B2 (en) 2021-03-31
US20190038704A1 (en) 2019-02-07
EP3169344B1 (en) 2021-09-29
EP3169344A2 (en) 2017-05-24
US10322161B2 (en) 2019-06-18
JP2017526644A (en) 2017-09-14

Similar Documents

Publication Publication Date Title
WO2016100985A3 (en) Chimeric antigen receptors and methods of use thereof
MY191581A (en) Anti-pd-1 antibodies
SG10201803042PA (en) Anti-tim-3 antibodies
HUE066591T2 (en) 8-cyano-5-piperidinoquinolines as TLR7/8 antagonists and their use in the treatment of immune disorders
CA2883095C (en) Antibody and protein formulations
WO2015200902A8 (en) Endophytes, associated compositions, and methods of use thereof
WO2017214170A3 (en) Baff-r antibodies and uses thereof
WO2016060996A3 (en) Interleukin-15 compositions and uses thereof
EP3200812A4 (en) Novel 4 7 peptide monomer and dimer antagonists
FR3021319B1 (en) PEPTIDES, COMPOSITIONS COMPRISING THE SAME, AND PARTICULARLY COSMETIC USES
MX2016012574A (en) Substituted heteroaryl compounds and methods of use.
WO2018075692A3 (en) Antibody constructs
WO2017023933A3 (en) Peptidomimetic macrocycles
EP3491026A4 (en) Human antibodies, pharmaceutical compositions and methods
PH12018502714A1 (en) Nicotine particles and compositions
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
WO2016089886A3 (en) Methods for treating dry eye disease by administering an il-6r antagonist
EP3318282A4 (en) DRUG DELIVERY VECTOR, AND COMPOSITION CONTAINING THE SAME
WO2015128746A3 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
WO2015200897A3 (en) Neural cells expressing adenovirus e4orf1, and methods of making and using the same
BR112016023899A2 (en) compositions comprising osteopontin derivatives for inhibiting hair growth
WO2016011201A3 (en) Epha4 cyclic peptide antagonists for neuroprotection and neural repair
WO2016133290A8 (en) Care terminal system device
EP3067423A4 (en) Human insecticidal gene and insecticidal peptide encoded thereby, and use thereof
EA201691702A1 (en) MTI CHEMICAL PROTEINS

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15821503

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2017501706

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015821503

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015821503

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15821503

Country of ref document: EP

Kind code of ref document: A2